Associations Between Two-Year Immune-Related Adverse Events and Psychological Distress and Subsequent Survival Outcomes Among ICI-Treated Survivors Diagnosed With Advanced Cancers in the US
{{output}}
Background: Immune-checkpoint Inhibitors (ICIs) are increasingly used in advanced cancers and can be associated with immune-related adverse events (irAEs). Aims: ... ...
